Pierre Daublain

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.4kcitations37works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

DNA and Nucleic Acid Chemistry(12), Advanced biosensing and bioanalysis techniques(10), Photochemistry and Electron Transfer Studies(7), Melanoma and MAPK Pathways(7), Computational Drug Discovery Methods(6)

Publications37 total

Model studies for the methylmalonyl-coenzyme A mutase-catalyzed isomerization reaction.
Figshare·2025Open Access
Abstract IA013: Discovery of the dual A2A/A2B receptor antagonist MK-1088 for the treatment of solid tumors
Molecular Cancer Therapeutics·2024Open Access
Abstract PR017: Discovery and clinical evaluation of a potent and selective A2A/2B dual receptor antagonist
Molecular Cancer Therapeutics·2023
Supplementary Figures from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Data from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Supplementary Figure Legends from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Supplementary Figure Legends from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Data from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Supplementary Figures from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery
Journal of Medicinal Chemistry·2022· 17 cited
Discovery of <b>MK-4688</b> : an Efficient Inhibitor of the HDM2–p53 Protein–Protein Interaction
Journal of Medicinal Chemistry·2021· 23 citedOpen Access
Flexibility in Drug Product Development: A Perspective
Molecular Pharmaceutics·2021· 8 cited
The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer
Journal of Medicinal Chemistry·2021· 33 citedOpen Access
IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies
European Journal of Pharmaceutics and Biopharmaceutics·2020· 37 citedOpen Access
Transcriptomic biomarkers to assess the liver and metabolic responses associated with bioactivation mechanisms of drug induced liver injury
Drug Metabolism and Pharmacokinetics·2019· 1 cited
Analyzing the Potential Root Causes of Variability of Pharmacokinetics in Preclinical Species
Molecular Pharmaceutics·2017· 25 cited
Formulation Strategies for High Dose Toxicology Studies
2017· 1 cited
Preclinical Dose Number and Its Application in Understanding Drug Absorption Risk and Formulation Design for Preclinical Species
Molecular Pharmaceutics·2015· 21 cited
Detailed Study of Precipitation of a Poorly Water Soluble Test Compound Using Methodologies as in Activity and Solubility Screening - Mixing and Automation Effects
Combinatorial Chemistry & High Throughput Screening·2013· 1 cited
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Cancer Discovery·2013· 674 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Frederick D. Lewis(13), Phieng Siliphaivanh(8), David Witter(8), Torsten Fiebig(8), Qiang Wang(8), Erick J. Morris(7), Sharda Jha(7), Clifford R. Restaino(7), Priya Dayananth(7), Donna Carr(7), Yongi Deng(7), Jenny Liu(7), Edward DiNunzio(7), William T. Windsor(7), Rumin Zhang(7), Minilik Angagaw(7), Elaine M. Pinheiro(7), Jagdish Desai(7), Gerald W. Shipps(7), Alan Hruza(7)